Capital Markets Assignment

Hamilton has acted for AlzeCure Pharma AB

Hamilton has act­ed for AlzeCure Pharma AB in con­nec­tion with its SEK 200 mil­lion IPO on Nasdaq First North Premier. First day of trad­ing is planned to oc­cur on 28 November 2018. The of­fer was made to the gen­er­al pub­lic in Sweden and Denmark and to in­sti­tu­tion­al in­vestors in Sweden and in­ter­na­tion­al­ly.

AlzeCure Pharma is a Swedish phar­ma­ceu­ti­cal re­search and de­vel­op­ment com­pa­ny de­vel­op­ing in­no­v­a­tive and ef­fec­tive drugs for the treat­ment of brain dis­ease, with a pri­ma­ry fo­cus on Alzheimer’s dis­ease.